Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No Concealing Cosmeceutical Claims From NAD, FTC

This article was originally published in The Tan Sheet

Executive Summary

Claims for cosmeceuticals referred by the National Advertising Division go to the same place on the Federal Trade Commission's list of priorities as other disputed claims - straight to the top
Advertisement

Related Content

Supplement GMP Warning Letters Make Modest Debut In 2010
Cosmeceutical Claims May Be Headed Into FDA's Radar
Cosmeceutical Claims May Be Headed Into FDA's Radar
Cosmeceutical Claims May Be Headed Into FDA's Radar
ERSP Refers NVE Pharmaceuticals’ AppuLoss Weight-Loss Ads To FTC
ERSP Refers NVE Pharmaceuticals’ AppuLoss Weight-Loss Ads To FTC
FTC Fines Oreganol Marketer $2.5 Million After Firm Ignores NAD Inquiry
NAD OKs 3 Of 15 Studies For Ameal BP Claims Substantiation
Ingestible Cosmeceuticals To Pick Up Speed In Three, Four Years, Exec Says
Redline Princess Claims Must Be Backed By Product-Specific Studies – NAD

Topics

Advertisement
UsernamePublicRestriction

Register

PS101872

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel